RxDoctor Payments DataLook up a doctor →

Roger Chapman

Nurse Practitioner · Tyler, TXNPI 1750805941

Payments from drug & device makers

$210,987in general payments, 2019–2025

Across 659 payments — averaging $320.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$180K
  • Axsome Therapeutics, Inc.$12K
  • Teva Pharmaceuticals USA, Inc.$11K
  • Impel Pharmaceuticals LLC$4K
  • Pfizer$1K
  • Impel Pharmaceuticals Inc.$799
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$2,0751%
  • Speaking & faculty fees$181,28986%
  • Travel & lodging$16,5298%
  • Food & beverage$11,0755%
  • Education$190%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$210,987 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$394,311
Medicare patients
368
Services billed
4,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant54$78,523
QuliptaAtogepant60$62,005
Nurtec OdtRimegepant Sulfate35$52,478
Ajovy AutoinjectorFremanezumab-Vfrm25$24,895
Aimovig AutoinjectorErenumab-Aooe30$20,662
Emgality PenGalcanezumab-Gnlm26$18,062
Acetaminophen-CodeineAcetaminophen With Codeine58$2,024
Gabapentin121$1,796
Tizanidine Hcl114$1,166
Lidocaine16$1,007
RizatriptanRizatriptan Benzoate39$789
Tramadol Hcl50$724
Topiramate73$657
Pregabalin23$595
Duloxetine Hcl22$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$180,458$140,528114 claims
PfizerNurtec Odt$1,119$52,47835 claims
Upsher-smith Laboratories LLCTopiramate$35$65773 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →